What is Veradermics's R&D?

Veradermics (MANE) reported R&D of $20.93M in Q1 2026.

How has Veradermics's R&D changed year-over-year?

Veradermics's R&D increased by 82.8% year-over-year, from $11.45M to $20.93M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Veradermics (MANE) R&D — Quarterly & Annual

Screener

R&D at other companies

Johnson & JohnsonJNJ

$3.65B+3.9%

OrganonOGN

$93M-3.1%

PVL

Palvella TherapeuticsPVLA

$9.33M+129%

TTR

Turn Therapeutics Inc.TTRX

$109.43K+1,082%

PTH

Pelthos TherapeuticsPTHS

$186K-4.1%

Krystal Biotech, Inc.KRYS

$15.33M+7.5%

Segments

By segment

See full

Reportable Segment$17.19M+50.2%

Other financials

Income statement

See full

Operating income-$29.9M-131%

Net income-$27.2M-120%

EPS (diluted)-$1.32+93.3%

Balance sheet

See full

Cash & equivalents$168.4M+419%

Total debt$4.0K—

Total equity$390.6M+744%

Total assets$397.4M—

Cash flow

See full

Operating cash flow-$21.2M-59.0%

CapEx--100%

Free cash flow-$21.2M-58.7%

Valuation

See full

Market cap$4.65B+269%

Returns & leverage

See full

Return on equity-28.7%—

Current ratio59.1×—

Where this comes from

Reported directly by Veradermics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Veradermics’s 10-Q, filed May 12, 2026.

Filed: May 12, 2026, 5:06 PM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q1 2026
Accession: 0001827635-26-000019

(in thousands, except share and per share amounts)	Three Months Ended March 31, 2026	Three Months Ended March 31, 2025
Operating expenses:
Research and development	$20,925	$11,447
General and administrative	8,937	1,468
Total operating expenses	29,862	12,915
Loss from operations	(29,862)	(12,915)
Other income:
Interest income	2,481	482
Other income	149	33

Item 1. Condensed Consolidated Financial Statements (

FAQ

What is Veradermics's R&D?: Veradermics (MANE) reported R&D of $20.93M in Q1 2026.
How has Veradermics's R&D changed year-over-year?: Veradermics's R&D increased by 82.8% year-over-year, from $11.45M to $20.93M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.